4. Corticosteroid use during steroid‐tapering phase.

	Solèr 2001	Busse 2001	Milgrom 2001	Holgate 2004	Pooled estimates
Baseline mean ICS dose (omalizumab/placebo)	766/777	564/522	284/267	1407/1376	N/A
Length of study (weeks)	52	28	28	32	N/A
Length of tapering phase	12	12	12	16	N/A
Mean daily ICS dose at end of tapering phase (omalizumab/placebo)	213/378 Source: FDA website	193/274 Source: FDA website	N/A	506/690 Source: unpublished data (Acumed)	N/A
Change in CS dose (omalizumab/placebo), mcg	Mean change (ICS): ‐553/‐399 Source: FDA website	Mean change (ICS): ‐371/‐278 Source: FDA website	N/A	Mean change (ICS): ‐782/‐596 Source: published paper	Busse 2001/Solèr 2001/Holgate 2004: WMD ‐119 mcg/d (95% CI ‐153.72 to ‐84.34)
Median (95% CI) daily ICS dose at end of tapering (omalizumab/placebo)	100 (0 to 400)/300 (100 to 600)	N/A	N/A	N/A	N/A
Change (%) (omalizumab/placebo)	72/51	66/50	Median change (ICS): 100/67 P = 0.001	Median change (ICS): 60/50 P = 0.003 Source: FDA website Median change (OCS): 69%/75% P = 0.7	N/A
Number of participants achieving > 50% reduction in ICS dose (n/N) (omalizumab/placebo)	216/274 150/272	194/268 141/257	174/216 68/101	94/126 61/120	OR 2.5 (95% CI 2.02 to 3.10) NNTB five to seven
Number of participants achieving complete ICS withdrawal (omalizumab/placebo)	118/274 53/272	106/268 49/257	119/216 39/101	27/126 18/120	OR 2.5 (95% CI 2.0 to 3.13) NNTB five to eight